BioPharma Dive July 25, 2024
On a conference call with analysts, CEO Thomas Schinecker said the company’s weight loss drugs, acquired via a $2.7 billion acquisition, can get to market “much faster” than investors expect.
Roche is best known for the cancer drugs that still account for much of its drug revenue. But the Swiss pharmaceutical giant spent much of its latest quarterly earnings call fielding questions about a pair of experimental weight loss medicines that have fast become important to its future growth.
Roche last year acquired those medicines in a $2.7 billion deal for biotechnology company Carmot Therapeutics. One, CT-388, is an injectable therapy, while the other, CT-996, is a pill. Since May, both have since shown the potential in early trials to...
Today's Sponsors
Today's Sponsor